Micro RNA-155 and antibody formation in transfusion patients
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at a substance called micro RNA-155 in patients who need regular blood transfusions. It aims to understand how it relates to the development of antibodies (alloantibodies) against transfused blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to get regular red blood cell transfusions and depend on them.
- You must be 5 years old or older.
- You must not have an autoimmune disease.
- You must not have an active infection or inflammatory condition.
- You must not be taking immunosuppressive therapy (medicines that lower your immune system).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
This gene therapy trial uses a modified virus to deliver a healthy gene into your own stem cells. The goal is to help your body make normal red blood cells so you may need fewer or no transfusions.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This study tests an experimental drug called YOLT-204 to see if it is safe and can help people with transfusion-dependent beta-thalassemia need fewer blood transfusions. It is for adults aged 18 to 35 who have a specific type of thalassemia and are otherwise healthy enough for the trial.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.